Danaher (NYSE: DHR) is acquiring Masimo (NASDAQ: MASI) for $9.9 billion in an all-cash deal that values the medical technology company at $180 per share. The transaction, announced February 17, 2026, ...

In this week’s edition of InnovationRx, we look at Jennifer Doudna’s $1 billion plan to bring Crispr gene editing to the real ...

On February 16, 2026, Masimo Corporation agreed to be acquired by Danaher Corporation in an all-cash merger that values Masimo at $180 per share, or about $9.9 billion, with the deal unanimously ...

Danaher Corp. is snapping up patient monitoring medtech Masimo in a $9.9 billion deal aimed at strengthening its diagnostics ...

Irvine-based Masimo is being acquired by Danaher Corp. in a deal with an enterprise value of about $9.9 billion, allowing it ...

Danaher is buying Masimo for $180 per share in cash. Here why MASI could push DHR stock higher in 2026. Danaher shares are ...

Danaher is buying Masimo for $180 per share in cash. Here why MASI could push DHR stock higher in 2026. Danaher shares are ...

For those who like to run the numbers, Danaher claims it is paying “18x estimated 2027 EBITDA, or 15x 2027 estimated EBITDA ...

Danaher Corp. announced Tuesday it will acquire Masimo Corp. in a blockbuster $9.9 billion transaction, including debt, a move set to reshape the global diagnostics landscape. Kirkland & Ellis LLP is ...

Danaher is acquiring Masimo for $9.9B, integrating its patient monitoring innovations to enhance diagnostics and drive growth in acute care settings.

Danaher Corporation has agreed to acquire Masimo in a cash deal worth $9.9bn in an effort to broaden its diagnostics business ...

Danaher 's days in the portfolio may be numbered. We're again left disappointed after Danaher's latest acquisition plan ...